RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23

Benzinga · 2d ago
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $22 to $23.